Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2022-08-10 Hansa Biopharma Hansa Biopharma AB: Riktlinjer för desensitiseringsbehandling av hög-sensitiserade njurtransplantationspatienter framtagna av ESOT i Transplant International Pressreleaser Ladda ner | Visa Stäng
2022-08-10 Hansa Biopharma Hansa Biopharma AB: European Society for Organ Transplantation's (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International Pressreleaser Ladda ner | Visa Stäng
2022-07-19 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma half year report 2022 Rapporter Ladda ner | Visa Stäng
2022-07-19 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharmas halvårsrapport januari - juni 2022 Rapporter Ladda ner | Visa Stäng
2022-07-18 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform Pressreleaser Ladda ner | Visa Stäng
2022-07-18 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma offentliggör en produktfinansieringstransaktion, utan utspädningseffekt, om 70 MUSD med NovaQuest. Transaktionen stödjer den fortsatta utvecklingen av Hansas enzymteknologiplattform Pressreleaser Ladda ner | Visa Stäng
2022-07-11 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma meddelar att första patienten behandlats i PAES-studien med Idefirix® (imlifidase) för behandling av högsensitiserade njurtransplantationspatienter Pressreleaser Ladda ner | Visa Stäng
2022-07-11 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Hansa Biopharma Hansa Biopharma AB: Increase of the number of votes in Hansa Biopharma Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Hansa Biopharma Hansa Biopharma AB: Ökning av antalet röster i Hansa Biopharma Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Hansa Biopharma Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Hansa Biopharma Kommuniké från årsstämma i Hansa Biopharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för första halvåret 2022 och ge en uppdatering av bolagets verksamhet Pressreleaser Ladda ner | Visa Stäng
2022-06-23 Finansinspektionen Finansinspektionen: Korrigering flaggningsmeddelande i Hansa Biopharma AB Pressreleaser Visa Stäng
2022-06-21 Finansinspektionen Finansinspektionen: Korrigering flaggningsmeddelande i Hansa Biopharma AB Pressreleaser Visa Stäng
2022-06-21 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Hansa Biopharma AB Pressreleaser Visa Stäng
2022-06-16 Hansa Biopharma Hansa Biopharma AB: NICE rekommenderar Hansa Biopharmas läkemedel Idefirix® (imlifidase) för desensitiseringsbehandling av högsensitiserade njurtransplantationspatienter Pressreleaser Ladda ner | Visa Stäng
2022-06-16 Hansa Biopharma Hansa Biopharma AB: NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 16 Jun 2022 | Hansa Biopharma

Hansa Biopharma AB: NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

  • NICE considers Idefirix® to be a clinically and cost-effective treatment within current clinical practice
  • The positive recommendation will enable access to this novel therapy for highly sensitized patients in England, Wales and potentially Northern Ireland

Lund, Sweden, June 16, 2022. Hansa Biopharma, ”Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today announces the recommendation by the National Institute for Health and Care Excellence (NICE) for its first-in-class treatment Idefirix® in the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor. NICE considers Idefirix® to be a clinically and cost-effective treatment.

The recommendation marks an important milestone for patients in England, Wales and Northern Ireland, as appropriate specialized transplant centres will be able to use Idefirix® to enable transplantation for highly sensitized patients, currently highly unlikely to receive a lifesaving compatible kidney transplant. The Medicines and Healthcare products Regulatory Agency’s (MHRA) granted conditional approval of imlifidase from the European Commission conditional approval in August 2020.2 The NICE recommendation builds upon this approval by considering the cost-effectiveness of Idefirix® in addition to its clinical efficacy and the significant unmet need of the patient population it treats.1

Kidney transplant candidates are classified  as highly sensitized if they have pre-formed antibodies against available donors known as human leukocyte antigens(HLA). These antibodies can carry the risk of causing damage to the transplanted kidney and potentially lead to rejection.3 Risk factors for becoming highly sensitized include previous transplantation, blood transfusion and pregnancy.4 Finding a match for these patients can be particularly difficult, meaning they spend a longer average time on transplant waiting lists, and therefore have an increased risk of dying while waiting for a suitable donor.5,6 The annual average number of kidney transplants in the U.K. over the last five years are 2,400 from deceased donors and 926 from living donors.7

”A lack of effective desensitization approaches has meant that until now, people who are classed as highly sensitized kidney patients in England have struggled to find a donor match, and have often had no alternative but to remain on long-term dialysis with a very poor quality of life,” says Dr Adnan Sharif, trustee at Kidney Research UK. ”We welcome this decision, which will allow new opportunities for certain highly sensitized patients to qualify for a life-altering transplant, and gain freedom from dialysis. Decision making around who has access to the treatment is key, and the lifespan of the transplanted kidneys will need to be carefully monitored.”

Long-term dialysis places a significant burden on both patients and healthcare systems, reducing health-related quality of life and increasing the risk of mortality and hospitalization.6,8-9

”We are thrilled that NICE has recommended Idefirix® as the first licensed therapy for highly sensitized kidney patients. These patients have serious disease burden and unmet needs and this recommendation is a significant milestone for them”, says Søren Tulstrup, President and CEO, Hansa Biopharma. ”For Hansa, this recommendation is also encouraging as we continue to pursue our vision: A world where patients with rare immunologic diseases can lead long and healthy lives”.

Hansa will work with national health service commissioners in England, Wales and Northern Ireland to support the implementation of the service in line with the NICE’s recommendations.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 07:00 CET on June 16, 2022.

— ENDS —

For more information:

Klaus Sindahl,Head of Investor Relations
M:+46 (0) 709 298 269
E:klaus.sindahl@hansabiopharma.com

Katja Margell, Head of Corporate Communications
M:+46 (0) 768 198 326
E:katja.margell@hansabiopharma.com

Notes to editors

About Idefirix® (imlifidase)

Imlifidase is an enzyme derived from the bacteriumStreptococcus pyogenesand has the ability to specifically target and cleave all classes of immunoglobulin G (IgG) antibodies.10

Imlifidase is a promising new strategy for desensitization of transplant patients with donor-specific anti-HLA (Human Leukocyte Antigens) antibodies (DSAs).11Highly sensitized patients have high levels of these preformed antibodies that can bind to the donor organ and damage the transplant.4Once they are inactivated with imlifidase, there is a window of opportunity for the transplant to take place. By the time the body starts to synthesize new IgG, the patient will be receiving immunosuppressive therapy to reduce the risk of organ rejection.

Theefficacyand safety of imlifidaseas a pre-transplant treatment to reduce donor-specific IgG was studied in four phase 2 open-label, single-arm, six-monthclinical trials.9,11-13

Hansa is now collecting further clinical evidence and will submit additionalefficacyand safety data based on one observational follow-up study and one post-approvalefficacystudy. Idefirix®was reviewed as part of the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) program, which supports medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.2

Idefirix®was granted conditional European Marketing Authorization from the EMA in August 2020 for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. The use of Idefirix®should be reserved for patients who are unlikely to be transplanted under the available kidney allocation system, including prioritization programs for highly sensitized patients.2Conditional approval allows the Agency to recommend a medicine formarketing authorization in cases where the benefit of a medicine’s immediate availability to patients outweighs the risk that not all the data are available yet.

About kidney failure

Kidney disease can progress to kidney failure or End-Stage Renal Disease (ESRD), identified when a patient’s kidney function is less than 15%.14ESRD poses a significant health burden, affecting nearly 2.5 million patients worldwide.13A kidney transplant is the treatment of choice for suitable patients with ESRD because it offers improved survival and quality of life benefits compared to long-term dialysis. There are approximately 80,000 kidney patients on transplant waiting lists across the European Union.15

Full product information can be accessed via the initial Summary of Product Characteristicsfoundhere ( https://www.hansabiopharma.com/mediatoolkit/ ).

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more atwww.hansabiopharma.com.

References

1. https://www.nice.org.uk/guidance/indevelopment/gid-ta10552/documents
2. European Medicines Agency. Available at: https://www.ema.europa.eu/en/news/new-treatment-enable-kidney-transplant-highly-sensitised-patients . Last accessed December 2021
3. Eurostam Report (A Europe-wide strategy to enhance transplantation of highly sensitized patients on the basis of acceptable HLA mismatches.) Available at https://cordis.europa.eu/project/id/305385/reporting . Last accessed April 2021
4. Manook M, et al.Lancet2017; 389(10070):727-734
5. Redfield R, et al.Nephrol Dial Transplant2016; 31:1746-1753
6. Lonze BE, et al.Ann Surg2018; 268(3):488-496
7. Database Global Observatory on Donation and Transplantation. Available at: http://www.transplant-observatory.org/data-charts-and-tables/ (https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.transplant-observatory.org%2Fdata-charts-and-tables%2F&data=05%7C01%7Ckatja.margell%40hansabiopharma.com%7Cb78300c9a9494b17e01a08da4d104ddb%7C2baeedcdecb6405a84aaec90b3dbc240%7C0%7C0%7C637907029669654132%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=YhHaxITyaCeA8nCfoQTw45pZv7KFx3%2FI7SBYXN0%2BAfQ%3D&reserved=0) .
8. Kuppachi S, et al. Transpl Int 2020; 33(3):251-259
9. Lorant T, et al. Am J Transplant2018;18(11):2752-2762
10. Hansa. Idefirix® Summary of Product Characteristics
11. Jordan SC, et al.N Engl J Med2017; 377(5):442-453
12. Winstedt L, et al.PLoS One2015; 10(7): e0132011
13. Jordan SC, et al.TransplantationOctober 21, 2020 – volume online first issue
14. NIH (2018). What is kidney failure? Available at: https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure . Last accessed May 2021
15. Newsletter Transplant 2020. pp 58-60.

2022-05-30 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma: Notice to Annual General Meeting Pressreleaser Ladda ner | Visa Stäng
2022-05-30 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma: Kallelse till årsstämma Pressreleaser Ladda ner | Visa Stäng
2022-05-30 Hansa Biopharma Hansa Biopharma AB: The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022 Pressreleaser Ladda ner | Visa Stäng
2022-05-30 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharmas valberedning nominerar Peter Nicklin till ny styrelseordförande inför årsstämman 2022 Pressreleaser Ladda ner | Visa Stäng
2022-05-23 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma har slutfört rekrytering till fas 2-studie av imlifidase som behandling av antikroppsmedierad avstötning (AMR) efter njurtransplantation Pressreleaser Ladda ner | Visa Stäng
2022-05-23 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation Pressreleaser Ladda ner | Visa Stäng
2022-05-13 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation Pressreleaser Ladda ner | Visa Stäng
2022-05-13 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma meddelar tidsbegränsat marknadsgodkännande i Schweiz för Idefirix[®] (imlifidase) inom njurtransplantation Pressreleaser Ladda ner | Visa Stäng
2022-04-21 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma interim report January - March 2022 Rapporter Ladda ner | Visa Stäng
2022-04-21 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharmas delårsrapport januari - mars 2022 Rapporter Ladda ner | Visa Stäng
2022-04-20 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2022-04-20 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma har tilldelats klassificering ASMR 3 i Frankrike för Idefirix® (imlifidase) som desensitiseringsbehandling för högsensitiserade njurtransplantationspatienter Pressreleaser Ladda ner | Visa Stäng
2022-04-19 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces U.S. FDA acceptance of Investigational New Drug (IND) application for Phase 3 study of imlifidase in anti-GBM disease Pressreleaser Ladda ner | Visa Stäng
2022-04-19 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma tillkännager FDA-godkännande av Investigational New Drug (IND)-ansökan i USA för fas 3-studie av imlifidase vid anti-GBM-sjukdom Pressreleaser Ladda ner | Visa Stäng
2022-04-08 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för januari-mars 2022 och ge en uppdatering av bolagets verksamhet Pressreleaser Ladda ner | Visa Stäng
2022-04-07 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma offentliggör årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng
2022-04-07 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma publishes Annual Report 2021 Rapporter Ladda ner | Visa Stäng
2022-03-28 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix[®] (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2022-03-28 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma och Medison Pharma tillkännager godkännande i Israel för Idefirix[®] (imlifidase) för desensitiseringsbehandling av högsensitiserade njurtransplantationspatienter Pressreleaser Ladda ner | Visa Stäng
2022-03-15 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2022-03-15 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma når överenskommelse om pris och subvention i Tyskland för Idefirix[®] (imlifidas) som desensitiseringsbehandling för högsensitiserade njurtransplantationspatienter Pressreleaser Ladda ner | Visa Stäng
2022-03-08 Hansa Biopharma Hansa Biopharma AB: Nyckeldata publicerade i JASN visar potentialen hos Hansa Biopharmas imlifidase att avsevärt förändra sjukdomsförloppet vid anti-GBM-sjukdom Pressreleaser Ladda ner | Visa Stäng
2022-03-08 Hansa Biopharma Hansa Biopharma AB: Key data demonstrating the potential of Hansa Biopharma's imlifidase to significantly alter course of anti-GBM disease published in JASN Pressreleaser Ladda ner | Visa Stäng
2022-02-25 Hansa Biopharma Hansa Biopharma AB: Franska Haute Autorité de Santé har fattat ett positivt beslut att ge tidig tillgång till Hansa Biopharmas Idefirix® (imlifidase) för desensitiseringsbehandling av högsensitiserade njurpatienter Pressreleaser Ladda ner | Visa Stäng
2022-02-25 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2022-02-03 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharmas bokslutskommuniké 2021 Rapporter Ladda ner | Visa Stäng
2022-02-03 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma year-end report 2021 Rapporter Ladda ner | Visa Stäng
2022-01-20 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma to host conference call to provide Year-End report for 2021 and Business Update Pressreleaser Ladda ner | Visa Stäng
2022-01-20 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera bolagets bokslutskommuniké för 2021 och ge en uppdatering av bolagets verksamhet Pressreleaser Ladda ner | Visa Stäng
2022-01-10 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Hansa Biopharma AB Pressreleaser Visa Stäng
2022-01-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma lämnar verksamhetsuppdatering inklusive viss finansiell nyckelinformation Pressreleaser Ladda ner | Visa Stäng
2022-01-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma provides business update including certain key financials Pressreleaser Ladda ner | Visa Stäng
2022-01-03 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma ingår avtal med AskBio för att utvärdera imlifidas som förbehandling till genterapi vid Pompes sjukdom Pressreleaser Ladda ner | Visa Stäng
2022-01-03 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease Pressreleaser Ladda ner | Visa Stäng
2021-12-30 Hansa Biopharma Increase of the number of shares and votes in Hansa Biopharma AB Pressreleaser Ladda ner | Visa Stäng
2021-12-30 Hansa Biopharma Hansa Biopharma AB: Ökning av antalet aktier och röster i Hansa Biopharma Pressreleaser Ladda ner | Visa Stäng
2021-12-29 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2021-12-29 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma rekryterar första patienten i USA till en randomiserad, kontrollerad pivotal studie av imlifidas hos högsensitiserade njurtransplantationspatienter Pressreleaser Ladda ner | Visa Stäng
2021-12-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma: Issue and repurchase of class C shares for incentive programs Pressreleaser Ladda ner | Visa Stäng
2021-12-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma: Emission och återköp av C-aktier för incitamentsprogram Pressreleaser Ladda ner | Visa Stäng
2021-12-08 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Hansa Biopharma AB Pressreleaser Visa Stäng
2021-12-07 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma och Medison Pharma ingår multiregionalt samarbete för kommersialisering av Hansas desensitiseringsbehandling inom njurtransplantation i centrala Östeuropa och Israel Pressreleaser Ladda ner | Visa Stäng
2021-12-07 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa's desensitization treatment for kidney transplant in Central Eastern Europe and Israel Pressreleaser Ladda ner | Visa Stäng
2021-11-15 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma avser att initiera en fas 3-studie med imlifidase för behandling av anti-GBM-sjukdom efter framgångsrikt rådgivningsmöte med FDA i USA Pressreleaser Ladda ner | Visa Stäng
2021-11-15 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA Pressreleaser Ladda ner | Visa Stäng
2021-11-12 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharmas valberedning utsedd Pressreleaser Ladda ner | Visa Stäng
2021-11-12 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma Nomination Committee formed Pressreleaser Ladda ner | Visa Stäng
2021-11-08 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma offentliggör att ett konfidentiellt utkast till registreringsdokument enligt Form F-1 har lämnats in till amerikanska SEC för en potentiell notering i USA Pressreleaser Ladda ner | Visa Stäng
2021-11-08 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO Pressreleaser Ladda ner | Visa Stäng
2021-10-21 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma interim report Jan-Sept 2021 Rapporter Ladda ner | Visa Stäng
2021-10-21 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma Delårsrapport januari-september 2021 Rapporter Ladda ner | Visa Stäng
2021-10-07 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma to host conference call to provide interim results for January-September 2021 and Business Update Pressreleaser Ladda ner | Visa Stäng
2021-10-07 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för januari-september 2021 och ge en uppdatering av bolagets verksamhet Pressreleaser Ladda ner | Visa Stäng
2021-09-01 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma presented new data on imlifidase at the European Society for Organ Transplantation (ESOT) Congress Pressreleaser Ladda ner | Visa Stäng
2021-09-01 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma presenterade nya data om imlifidase på ESOT-kongressen (European Society for Organ Transplantation) Pressreleaser Ladda ner | Visa Stäng
2021-08-31 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar Pressreleaser Ladda ner | Visa Stäng
2021-08-31 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma informerar om höstens investerar-konferenser och presenterar en uppdaterad finansiell kalender Pressreleaser Ladda ner | Visa Stäng
2021-08-25 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma achieves Great Place to Work certification for second consecutive year Pressreleaser Ladda ner | Visa Stäng
2021-08-25 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma får Great Place to Work-certifiering för andra året i rad Pressreleaser Ladda ner | Visa Stäng
2021-08-02 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharmas läkemedel Idefirix[®] (imlifidase) för desensitisering av högsensitiserade njurtransplantationspatienter subventioneras i Nederländerna Pressreleaser Ladda ner | Visa Stäng
2021-08-02 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces reimbursement in the Netherlands of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2021-07-15 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma interim report Jan-June 2021 Rapporter Ladda ner | Visa Stäng
2021-07-15 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma Delårsrapport januari-juni 2021 Rapporter Ladda ner | Visa Stäng
2021-07-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation Pressreleaser Ladda ner | Visa Stäng
2021-07-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma offentliggör långtidsdata som visar en 3-årig graftöverlevnad på 84 procent efter behandling med imlifidase och transplantation Pressreleaser Ladda ner | Visa Stäng
2021-07-01 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för första halvåret 2021 och ge en uppdatering av bolagets verksamhet Pressreleaser Ladda ner | Visa Stäng
2021-07-01 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update Pressreleaser Ladda ner | Visa Stäng
2021-06-28 Hansa Biopharma Hansa Biopharma AB: NT-rådet har beslutat att rekommendera Hansa Biopharmas behandling Idefirix[®] (imlifidase) som desensitiseringsbehandling för högsensitiserade patienter som väntar på njurtransplantation Pressreleaser Ladda ner | Visa Stäng
2021-06-28 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces decision by Swedish New Therapies Council to recommend use of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2021-06-23 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma announces study design for a US randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients Pressreleaser Ladda ner | Visa Stäng
2021-06-23 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma tillkännager designen för en USA baserad randomiserad kontrollerad imlifidase-studie i högsensitiserade njurtransplantationspatienter Pressreleaser Ladda ner | Visa Stäng
2021-05-12 Hansa Biopharma Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-12 Hansa Biopharma Kommuniké från årsstämma i Hansa Biopharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-04-22 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma Delårsrapport januari-mars 2021 Rapporter Ladda ner | Visa Stäng
2021-04-22 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma interim report Jan-Mar 2021 Rapporter Ladda ner | Visa Stäng
2021-04-14 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för första kvartalet 2021 och ge en uppdatering av bolagets verksamhet Pressreleaser Ladda ner | Visa Stäng
2021-04-14 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update Pressreleaser Ladda ner | Visa Stäng
2021-04-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma: Notice to Annual General Meeting Pressreleaser Ladda ner | Visa Stäng
2021-04-09 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma: Kallelse till årsstämma Pressreleaser Ladda ner | Visa Stäng
2021-04-08 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Hansa Biopharma AB Pressreleaser Visa Stäng
2021-04-08 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma publishes Annual Report 2020 Rapporter Ladda ner | Visa Stäng
2021-04-08 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma offentliggör årsredovisning för 2020 Rapporter Ladda ner | Visa Stäng
2021-04-07 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Hansa Biopharma AB Pressreleaser Visa Stäng
2021-03-29 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma enters preclinical research collaboration with argenx Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma ingår prekliniskt forskningssamarbete med argenx Pressreleaser Ladda ner | Visa Stäng
2021-03-01 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development Pressreleaser Ladda ner | Visa Stäng
2021-03-01 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma utser dr Magnus Korsgren till chef för forskning och utveckling Pressreleaser Ladda ner | Visa Stäng
2021-02-04 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma Bokslutskommuniké 2020 Rapporter Ladda ner | Visa Stäng
2021-02-04 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma year-end report Jan-Dec 2020 Rapporter Ladda ner | Visa Stäng
2021-01-27 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update Pressreleaser Ladda ner | Visa Stäng
2021-01-27 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma bjuder in till en webbsänd telefonkonferens av bolagets bokslutskommuniké för 2020 samt ge en uppdatering av bolagets verksamhet Pressreleaser Ladda ner | Visa Stäng
2021-01-11 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference Pressreleaser Ladda ner | Visa Stäng
2021-01-11 Hansa Biopharma Hansa Biopharma AB: Hansa Biopharma ger en verksamhetsuppdatering inkl. vissa finansiella nyckeltal inför JP Morgan Global Healthcare Conference Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

20 Oct 2022 | Kvartalsrapport 2022-Q3